- IN₹232.54m
- IN₹205.60m
- 18
- 22
- 54
- 19
Annual balance sheet for Bacil Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2.38 | 4.92 | 2.2 | 0.415 | 28.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0 | 0 | 0 | 0 | — |
Total Other Current Assets | |||||
Total Current Assets | 3.02 | 5.02 | 2.29 | 0.521 | 29.1 |
Net Property, Plant And Equipment | 0.146 | 0.109 | 0.082 | 0.062 | 0 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 40.9 | 12.7 | 11.3 | 13.3 | 256 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 27 | 0.472 | 0.279 | 1.13 | 1.69 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 27 | 0.472 | 0.279 | 1.13 | 1.69 |
Common Stock | |||||
Other Equity | |||||
Total Equity | 13.9 | 12.2 | 11 | 12.1 | 254 |
Total Liabilities & Shareholders' Equity | 40.9 | 12.7 | 11.3 | 13.3 | 256 |
Total Common Shares Outstanding |